Sterility Testing Market Size

Sterility Testing Market Analysis

The Sterility Testing Market size is estimated at USD 1.43 billion in 2024, and is expected to reach USD 2.43 billion by 2029, growing at a CAGR of 11.10% during the forecast period (2024-2029).

The COVID-19 pandemic impacted the growth of the sterility testing market. Sterility testing was a key tool for most pharmaceutical and biotechnological companies that started focusing on their research and development for the identification of leads that can diagnose and treat the SARS-CoV-2 infection. The increase in COVID-19 cases drove the major companies and research institutions to look outside of conventional medicine or medicines, which resulted in significant investment in research and development efforts by both private and public entities worldwide. These activities have significantly boosted the sterility testing market. Moreover, the severity and high infection rate of infections and the growing number of drugs and vaccines led to high demand for sterility testing in the pharmaceutical and biopharmaceutical production industry. This has increased the demand for strict sterility testing of the products. With the rising adoption and demand for sterility testing, the studied market is expected to regain its full potential in the next two to three years.

Factors such as the increasing research and development in life sciences, rising number of drug launches, and rise in demand for sterilized products are boosting the market growth. In addition, the rising demand for sterilized products globally and a few potential safety issues connected to the products, which typically result from manufacturing processes and complex biological and structural characteristics of the products, are anticipated to drive the market during the forecast period.

The rising burden of chronic and infectious diseases among the population raises the demand for strict sterility testing of drugs and medical devices to ensure the safety of the products and devices. This is anticipated to fuel the market growth over the forecast period. For instance, according to the British Heart Foundation England Factsheet, published in January 2022, about 6.4 million people were living with cardiovascular diseases in England in 2021. In addition, as per the same source, around 7.4 million people were living with heart and circulatory diseases in the United Kingdom in 2021. Also, as per the data published by WHO, in October 2022, the incidence of tuberculosis was estimated to be around 10.6 million people globally in 2021, of which 1.2 million were children.

Additionally, the increasing number of chronic diseases further increases the demand for effective drugs, which is also expected to propel the need for sterility tests of the drugs before launching them into the market, thereby fuelling the market growth. For instance, in September 2022, the Government of India launched a vaccine against cervical cancer Quadrivalent Human Papillomavirus vaccine (qHPV), which has been developed by the Serum Institute of India (SII) and the Department of Biotechnology (DBT). Also, in September 2022, Bayer launched vericiguat in India to reduce the risk of cardiovascular deaths and repeated hospitalizations.

Furthermore, the increasing research and development in the field of life sciences, coupled with huge public and private funding in the sector, is also contributing to the market growth. For instance, as per the Union Budget for the year 2021-2022, the Indian Ministry of Science and Technology allocated a budget of INR 35 billion, a 25% hike from the 2020-21 budget, for the Department of Biotechnology (DBT) of India, mainly for biotechnology research and development and industrial and entrepreneurship development in the country which will boost the studied market.

Moreover, the growing company activities in adopting various business strategies such as expansion, collaboration, and others are also contributing to the market growth. For instance, in September 2021, Nelson Labs and Sterigenics Germany GmbH, global leaders in comprehensive laboratory testing and sterilization services, announced the opening of a newly expanded center of excellence for microbiological laboratory testing as well as increased sterilization capacity in their Wiesbaden, Germany, facilities.

Therefore, owing to the aforementioned factors, the studied market is expected to grow over the forecast period. However, the stringent regulatory framework is expected to hinder the growth of the sterility testing market over the forecast period.